0A4C.L - Altimmune, Inc.

LSE - LSE Delayed price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.09
52-week change 3-22.16%
S&P500 52-week change 31.77%
52-week high 323.1700
52-week low 33.9211
50-day moving average 35.2457
200-day moving average 311.2844

Share statistics

Avg vol (3-month) 319.67k
Avg vol (10-day) 3745
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 842.61M
% held by insiders 10.83%
% held by institutions 192.85%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023


Profit margin 0.00%
Operating margin (ttm)111,562.02%

Management effectiveness

Return on assets (ttm)-28.05%
Return on equity (ttm)-48.42%

Income statement

Revenue (ttm)-79k
Revenue per share (ttm)-0.00
Quarterly revenue growth (yoy)-34.40%
Gross profit (ttm)-70.52M
Net income avi to common (ttm)-85.36M
Diluted EPS (ttm)-2.3890
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)165.73M
Total cash per share (mrq)3.36
Total debt (mrq)1.01M
Total debt/equity (mrq)0.61
Current ratio (mrq)11.58
Book value per share (mrq)3.40

Cash flow statement

Operating cash flow (ttm)-68.47M
Levered free cash flow (ttm)-47.64M